 |
| Carl Icahn |
Gladstone Place Partners is working for San Diego-based biotech Illumina Inc. as it battles activist investor Carl Icahn, who has nominated three directors to its board of directors.
In his open letter to shareholders, Icahn expressed his opposition to Illumina's $7.1B acquisition of cancer testing company Grail, which it had developed and then spun off in 2017.
He claims $50 billion of value has been wiped from the company’s market capitalization since the closing of the deal.
Icahn wrote: “This value destruction is a direct result of a series of ill-advised (and frankly inexplicable) actions taken by the board of directors of our company in connection with the acquisition of GRAIL, Inc. To paraphrase William Shakespeare’s Hamlet, something is rotten in the state of Illumina.”
The company counters that Icahn’s nominees lack relevant skills and experience.
Illumina CEO Francis deSouza and independent chair John Thompson had multiple conversations with Icahn.
They found him “explicit and unyielding in his demand that any resolution should give him outsized influence and control.”
Gladstone Place CEO Steve Lipin handles Illumina.
Prosek Partners handles New York’s Tilray Brands, craft beer & cannabis operation, as it acquires BrewDog, a leading British independent beer producer in the UK, for $45M.
Brunswick Group handles Zurich Insurance as it agrees to buy UK-based Beazley specialty insurer in a deal valued at $11B.
FGS Global represents Brink’s as it agrees to acquire NCR Atleos, which relies on Collected Strategies, in a $6.6B cash & stock deal to create a leading fintech infrastructure company. (Updated)
A January article in O’Dwyer’s proposes that in 2026, the strongest financial brands will not simply tell compelling stories—they will “signal readiness.”
C Street Advisory Group is working the Chapter 11 filing of Axip Energy Services as it unloads its nearly all of its assets to deal with a heavy debt load.
